TriSalus Life Sciences, Inc. TLSI
3.64 USD -0.25 (-6.43%)
Nov 5, 2026, 12:59 PM EST
3.57 Day range 3.90
2.20 52-week range 7.95
- YTD
- -47.85%
- 1 year
- -18.20%
Financial health
Altman Z-Score
-4.54 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
D+1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -3.8×
FY 2020 5y median -4.0× FY 2025
P/S 5.9×
FY 2020 5y median 12.1× FY 2025
P/B -7.8×
FY 2020 5y median -7.8× FY 2025
P/FCF -14.0×
FY 2020 5y median -9.0× FY 2025
EV/EBITDA -8.4×
FY 2020 5y median -6.2× FY 2025
EV/Sales 6.2×
FY 2020 5y median 11.5× FY 2025
FCF Yield -7.2%
FY 2020 5y median -11.1% FY 2025
Profitability
Gross Margin 84.6%
FY 2020 5y median 85.8% FY 2025
Operating Margin -59.7%
FY 2020 5y median -286.1% FY 2025
Net Margin -86.9%
FY 2020 5y median -320.7% FY 2025
ROE 115.8%
FY 2020 5y median 128.3% FY 2025
ROIC -112.3%
FY 2020 5y median -112.3% FY 2025
ROA -111.0%
FY 2020 5y median -138.6% FY 2025
Growth (YoY)
Revenue 53.4%
FY 2020 FY 2025
Operating Income 25.5%
FY 2020 FY 2025
EPS (diluted) -47.2%
FY 2020 FY 2025
Free Cash Flow 54.0%
FY 2020 FY 2025
Financial Health
Current Ratio 2.8×
FY 2020 5y median 2.0× FY 2025
Quick Ratio 2.5×
FY 2020 5y median 1.6× FY 2025
Debt / Equity -1.0×
FY 2020 5y median -0.2× FY 2025
Net Debt / EBITDA -0.4×
FY 2020 5y median 0.2× FY 2025
Interest Coverage -4.9×
FY 2020 5y median -13.6× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31